Medistim ASA
OSE:MEDI

Watchlist Manager
Medistim ASA Logo
Medistim ASA
OSE:MEDI
Watchlist
Price: 266 NOK 1.14%
Market Cap: 4.9B NOK

Medistim ASA
Investor Relations

Medistim ASA engages in the development, manufacturing, and distribution of medical equipment and consumables. The company is headquartered in Oslo, Oslo. The company went IPO on 2004-05-28. The company develops, manufactures and distributes medical devices primarily for cardiac and vascular surgery. The firm provides intra-operative standard control applications designed to verify and document quality during surgery. Its product portfolio comprises systems, such as ultrasound imaging systems VeriQ C and MiraQ, as well as probes, which offer Transit Time Flow Measurement (TTFM). The Company’s activities are divided into four business areas: lease of equipment within cardiac surgery, capital and consumable sales within cardiac surgery, sales of electronic stethoscopes and distribution and sales of third party products. Furthermore, the Company is a parent of Medistim USA Inc, Medistim Deutschland GmbH, and Medistim Norge AS, among others.

Show more
Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Last Earnings Call
Fiscal Period
Q3 2025
Call Date
Oct 24, 2025
AI Summary
Q3 2025

Record Quarter: Medistim delivered its best ever third quarter, with sales of NOK 166.8 million, up 25.7%, and operating profit (EBIT) up 27.1%.

Growth Drivers: The Americas region led the growth, contributing 63% of the Q3 increase, with sales up 35.7%. Asia Pacific also saw exceptional growth at 194%.

Margin Improvement: Gross margin improved by 1.2 percentage points to 81.5%, despite higher sales of lower-margin imaging products.

Price Increase Withstood: Recent price increases in the U.S. did not deter sales volumes, with strong probe sales achieved at higher prices.

Vascular Segment Slower: Vascular product growth slowed to 3.7% for the quarter after strong first half performance, but management expressed confidence in future growth.

Rising Costs: Operating expenses rose, mainly due to increased commissions and incentives linked to strong sales, but profit growth outpaced cost growth.

Strong Cash Flow: The company ended the quarter with strong operational cash flow and a cash position of NOK 157.7 million.

Key Financials
Revenue
NOK 166.8 million
Operating Profit
NOK 40.6 million
Gross Margin
81.5%
Profit After Tax (Q3)
NOK 34.7 million
EBITDA (Q3)
NOK 46.4 million
Year-to-Date Revenue
NOK 517.5 million
Year-to-Date Operating Profit
NOK 153.9 million
Year-to-Date Profit After Tax
NOK 121.1 million
Cash Position
NOK 157.7 million
Inventory
NOK 167 million
Recurring Revenue Share (Q3)
72%
Americas Sales
NOK 83.2 million
Asia Pacific Sales
NOK 25.2 million
EMEA Sales
NOK 37.1 million
Earnings Call Recording
Other Earnings Calls

Management

Ms. Kari Eian Krogstad
CEO & President
No Bio Available
Mr. Thomas Jakobsen
Chief Financial Officer
No Bio Available
Mr. Helge Borslid
Vice President of Operations
No Bio Available
Ms. Hæge Johanne Krogh Wetterhus
Vice President of Marketing
No Bio Available
Mr. Hakon Grothe
Chief Innovation Officer
No Bio Available
Mr. Ole Arne Eiksund
Chief Business Development Officer
No Bio Available
Mr. Mike Farbelow
President of Medistim USA Inc
No Bio Available
Mr. Roger Reino Morberg
Vice President of Sales - APAC
No Bio Available
Ms. Stephanie D'Avout Stenhagen
Vice President of Sales EMEA
No Bio Available
Mr. Ole Jorgen Robsrud
Managing Director of Medistim Norge AS
No Bio Available

Contacts

Address
OSLO
Oslo
Okernveien 94
Contacts
+4723059660.0
www.medistim.com